MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
0.7660
-0.0300
-3.77%
Closed 16:04 07/11 EDT
OPEN
0.7800
PREV CLOSE
0.7960
HIGH
0.7996
LOW
0.7050
VOLUME
220.95K
TURNOVER
0
52 WEEK HIGH
1.989
52 WEEK LOW
0.4500
MARKET CAP
57.72M
P/E (TTM)
-1.1529
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CUE last week (0707-0711)?
Weekly Report · 10h ago
Weekly Report: what happened at CUE last week (0630-0704)?
Weekly Report · 07/07 10:52
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 07/01 21:05
Cue Biopharma Amends License Agreement with MIL 40G
TipRanks · 07/01 20:43
Cue Biopharma announces presentation of new CUE-101 data
TipRanks · 07/01 20:20
Cue Biopharma Issues Update On Its Clinical Stage Asset, CUE-101, Representative Of CUE-100 Series; Data Highlights Include ORR Of 50% In Treatment-Naive Patients With HPV+ R/M HNSCC
Benzinga · 07/01 20:08
CUE BIOPHARMA INC - 12-MONTH SURVIVAL OF 88% AND MOS OF 32 MONTHS
Reuters · 07/01 20:05
CUE BIOPHARMA PROVIDES UPDATE ON MOST ADVANCED CLINICAL STAGE ASSET, CUE-101, PRESENTED BY DR. DIMITRIOS COLEVAS AT THE DAVA 4TH HAWAII GLOBAL SUMMIT ON THORACIC MALIGNANCIES
Reuters · 07/01 20:05
More
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.